Startups
15:02
11:31
The three major A-share indices fell collectively in the morning trading today. As of noon, the Shanghai Composite Index fell 6.34%, the Shenzhen Component Index fell 8.01%, the ChiNext Index fell 9.74%, and the Beijing Stock Exchange 50 Index fell 10.04%. The market's half-day turnover was 1,089.2 billion yuan, an increase of 342.9 billion yuan from the previous day. More than 5,211 stocks fell in the market, and more than 1,400 stocks in the two markets hit the limit. In terms of sector themes, the agriculture and breeding sectors rose against the trend; the consumer electronics and copper cable high-speed connection sectors fell sharply. On the market, all kinds of mainstream A-share indexes fell collectively, with the Shanghai Composite 50 Index falling more than 5%, the CSI 300 Index falling more than 6%, the CSI 1000 Index falling nearly 9%, the micro-cap index falling more than 9%, and the CSI 2000 Index falling more than 10%; the agriculture, GMO, and breeding sectors rose against the market trend, with Shennong Seed, Dunhuang Seed, Beidahuang, Wanxiang Denong, Fucheng Shares, Xiangjia Shares, Jinhe Bio and many other stocks hitting the daily limit, and Xiaoming Shares and Kangnong Seed were among the top gainers; the consumer electronics sector continued to fall, with more than 20 stocks such as Goertek, Luxshare Precision, Fu Ri Electronics, Lianchuang Optoelectronics, Edifier, and Foxconn Industrial Internet hitting the daily limit. As for hot stocks, Kaimet Gas staged a ground-to-sky board in the early trading, recording 6 boards in 7 days.
20:47
Guotai Junan Securities Research Report believes that with the empowerment of AI, the shortened R&D cycle, reduced costs, and improved efficiency will all boost the IRR level of innovative pharmaceutical companies from a medium-term perspective, and the sector may be expected to usher in a new growth logic. The recovery of investment and financing activities in the global pharmaceutical industry is conducive to the improvement of financing cash flow of innovative pharmaceutical companies. In the significant upward stage of the industry's investment and financing cycle, the innovative drug sector tends to perform better in the capital market. For example, referring to the previous round from 2019 to 2021. At the same time, the central axis of US Treasury bond interest rates is likely to move downward in 2025, which may further benefit the continuation of the recovery trend in financing activities of innovative pharmaceutical companies and boost the sector's valuation. Waiting for fiscal support, there is room for innovative drug companies to repair their gross profit margins. On the one hand, the imminent release of industry policies represented by the "Class C Catalogue" may be an important catalyst for the recovery of sector valuations and sentiment. On the other hand, "social security injection" may be one of the options for fiscal support, thereby alleviating the pressure on medical insurance payments and driving the continued recovery in the growth rate of basic medical insurance expenditures. The revenue growth rate of the innovative drug sector is expected to usher in an upward inflection point, and the gross profit margin is also expected to be repaired. The "valuation expansion elasticity and space" of innovative drugs listed on the Hong Kong stock market may be stronger than that of A-shares.
17:41
15:52
10:29
09:56
13:43
09:26
04:47
11:40
11:22
11:18
09:47
06:53
Load More
Email Subscription
Newsletters and emails are now available! Delivered on time, every weekday, to keep you up to date with North American business news.
ASIA TECH WIRE

Grasp technology trends

Download